Insulin lispro (ultra rapid formulation) - Eli lilly

Drug Profile

Insulin lispro (ultra rapid formulation) - Eli lilly

Alternative Names: LY-900014

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Phase I Diabetes mellitus

Most Recent Events

  • 12 Oct 2017 Eli Lilly plans a phase I trial for Type-2 diabetes mellitus in Germany(NCT03305822)
  • 22 Sep 2017 Eli Lilly plans a phase I trial for Type-2 diabetes mellitus (In volunteers) in Germany (NCT03286751)
  • 12 Sep 2017 Pharmacokinetics and adverse events data from a phase I trial in Diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top